{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:46:39Z","timestamp":1759538799481,"version":"build-2065373602"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AI159396"],"award-info":[{"award-number":["K23AI159396"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To examine the effect of a loading dose (LD) for extended infusion piperacillin\/tazobactam on clinical outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-centre, retrospective cohort study evaluated adult patients with Gram-negative bacteraemia who received extended infusion piperacillin\/tazobactam for \u226548\u2005hours between 2015 and 2022. In December 2019, the study institution developed a policy that automatically ordered a piperacillin\/tazobactam LD whenever piperacillin\/tazobactam was prescribed. The study compared patients who received piperacillin\/tazobactam LD to those who did not. The primary endpoint was 30-day all-cause mortality. Key secondary endpoints included clinical cure, 14-day all-cause mortality, in-hospital all-cause mortality and microbiologic cure. Logistic regression modelling was performed to control for confounding variables.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 151 patients were included in the analysis, with 84 patients in the LD group and 67 patients in the no LD group. Baseline characteristics were similar in both treatment groups, except for immunocompromised status, severity of illness and serum creatinine, with most mortality prognosticators in the LD group. In the bivariate analysis, 30-day mortality was 10.7% (9\/84) in the LD group compared to 9.0% (6\/67) in the no LD group (P\u200a=\u200a0.72). This was consistent with the multivariable logistic regression model (adjusted OR, 0.71; 95% CI, 0.21\u20132.41).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Overall, we observed no significant association between LD for extended infusion piperacillin\/tazobactam and mortality, and no signal that use of LD was associated with more adverse events. We hypothesize a potential benefit of LD administration for severely ill patients, but larger adequately powered prospective cohorts or randomized trials are needed to examine this.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf259","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T04:25:44Z","timestamp":1754281544000},"page":"2635-2643","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of piperacillin\/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7524-6898","authenticated-orcid":false,"given":"Savan","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey , Piscataway, NJ ,","place":["USA"]},{"name":"Department of Pharmacy, Robert Wood Johnson University Hospital , New Brunswick, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana","family":"Mohayya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Robert Wood Johnson University Hospital , New Brunswick, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsheena","family":"Yassin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Robert Wood Johnson University Hospital , New Brunswick, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Dao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey , Piscataway, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Aboujaoude","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey , Piscataway, NJ ,","place":["USA"]},{"name":"Department of Pharmacy, Robert Wood Johnson University Hospital , New Brunswick, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinki J","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Infectious Diseases, Robert Wood Johnson Medical School, Rutgers, the State University of New Jersey , Piscataway, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abdul Azim","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Infectious Diseases, Robert Wood Johnson Medical School, Rutgers, the State University of New Jersey , Piscataway, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith S","family":"Kaye","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Infectious Diseases, Robert Wood Johnson Medical School, Rutgers, the State University of New Jersey , Piscataway, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-5434","authenticated-orcid":false,"given":"Nathaniel J","family":"Rhodes","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Department of Pharmacy Practice, Midwestern University , Downers Grove, IL ,","place":["USA"]},{"name":"College of Pharmacy, Pharmacometrics Center of Excellence, Midwestern University , Downers Grove, IL ,","place":["USA"]},{"name":"Department of Pharmacy, Northwestern Memorial Hospital , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-6130","authenticated-orcid":false,"given":"Marc H","family":"Scheetz","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Department of Pharmacy Practice, Midwestern University , Downers Grove, IL ,","place":["USA"]},{"name":"College of Pharmacy, Pharmacometrics Center of Excellence, Midwestern University , Downers Grove, IL ,","place":["USA"]},{"name":"Department of Pharmacy, Northwestern Memorial Hospital , Chicago, IL ,","place":["USA"]},{"name":"College of Graduate Studies, Departments of Pharmacology and Biomedical Sciences, Midwestern University , Downers Grove, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5071-9193","authenticated-orcid":false,"given":"Navaneeth","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey , Piscataway, NJ ,","place":["USA"]},{"name":"Department of Pharmacy, Robert Wood Johnson University Hospital , New Brunswick, NJ ,","place":["USA"]},{"name":"Division of Allergy, Immunology, and Infectious Diseases, Robert Wood Johnson Medical School, Rutgers, the State University of New Jersey , Piscataway, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"2025100314242654200_dkaf259-B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2025100314242654200_dkaf259-B2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-d","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025100314242654200_dkaf259-B3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/phar.2842","article-title":"International Consensus Recommendations for the Use of Prolonged-Infusion Beta-Lactam Antibiotics: endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2025100314242654200_dkaf259-B4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/phar.2905","article-title":"Correction to \u201cInternational Consensus Recommendations for the Use of Prolonged-Infusion Beta-Lactam Antibiotics: endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists\u201d","volume":"44","year":"2024","journal-title":"Pharmacotherapy"},{"key":"2025100314242654200_dkaf259-B5","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025100314242654200_dkaf259-B6","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1128\/AAC.01956-15","article-title":"Defining clinical exposures of cefepime for Gram-negative bloodstream infections that are associated with improved survival","volume":"60","author":"Rhodes","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025100314242654200_dkaf259-B7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T\u200a&gt;\u200aMIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2025100314242654200_dkaf259-B8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/jac\/dkz437","article-title":"\u03b2-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill","volume":"75","author":"Wong","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025100314242654200_dkaf259-B9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2165\/11595960-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study","volume":"28","author":"Zhou","year":"2011","journal-title":"Drugs Aging"},{"key":"2025100314242654200_dkaf259-B10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2025100314242654200_dkaf259-B11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijantimicag.2011.10.011","article-title":"Continuous infusion of piperacillin\/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs","volume":"39","author":"Duszynska","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2025100314242654200_dkaf259-B12","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"2025100314242654200_dkaf259-B13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciu402","article-title":"Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes","volume":"59","author":"Rhodes","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025100314242654200_dkaf259-B14","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/cid\/ciu403","article-title":"Reply to Rhodes et al.","volume":"59","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"author":"FDA. Zosyn (piperacillin and tazobactam) for injection","key":"2025100314242654200_dkaf259-B15"},{"author":"CLSI","key":"2025100314242654200_dkaf259-B16"},{"key":"2025100314242654200_dkaf259-B17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ijantimicag.2015.01.007","article-title":"Subtleties in practical application of prolonged infusion of \u03b2-lactam antibiotics","volume":"45","author":"De Waele","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2025100314242654200_dkaf259-B18","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"2025100314242654200_dkaf259-B19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13054-015-0750-y","article-title":"Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?","volume":"19","author":"Udy","year":"2015","journal-title":"Crit Care"},{"key":"2025100314242654200_dkaf259-B20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/1471-2334-11-181","article-title":"Does prolonged \u03b2-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials","volume":"11","author":"Tamma","year":"2011","journal-title":"BMC Infect Dis"},{"key":"2025100314242654200_dkaf259-B21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/cid\/cis857","article-title":"Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin\/tazobactam: a systematic review and meta-analysis","volume":"56","author":"Falagas","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025100314242654200_dkaf259-B22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijantimicag.2014.01.027","article-title":"Prolonged infusion versus intermittent boluses of \u03b2-lactam antibiotics for treatment of acute infections: a meta-analysis","volume":"43","author":"Teo","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2025100314242654200_dkaf259-B23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025100314242654200_dkaf259-B24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40560-020-00490-z","article-title":"Prolonged versus intermittent \u03b2-lactam antibiotics intravenous infusion strategy in sepsis or septic shock patients: a systematic review with meta-analysis and trial sequential analysis of randomized trials","volume":"8","author":"Kondo","year":"2020","journal-title":"J Intensive Care"},{"key":"2025100314242654200_dkaf259-B25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/jcpt.13301","article-title":"Loading dose and efficacy of continuous or extended infusion of beta-lactams compared with intermittent administration in patients with critical illnesses: a subgroup meta-analysis and meta-regression analysis","volume":"46","author":"Wu","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"2025100314242654200_dkaf259-B26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"key":"2025100314242654200_dkaf259-B27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jama.2024.9779","article-title":"Continuous vs intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomized clinical trial","volume":"332","author":"Dulhunty","year":"2024","journal-title":"JAMA"},{"key":"2025100314242654200_dkaf259-B28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ijantimicag.2018.03.024","article-title":"Nephrotoxicity of piperacillin\/tazobactam combined with vancomycin: should it be a concern?","volume":"52","author":"Balc\u0131","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2025100314242654200_dkaf259-B29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jceh.2012.05.002","article-title":"An update on drug-induced liver injury","volume":"2","author":"Devarbhavi","year":"2012","journal-title":"J Clin Exp Hepatol"},{"key":"2025100314242654200_dkaf259-B30","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/09537104.2018.1468025","article-title":"Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature","volume":"29","author":"Alzahrani","year":"2018","journal-title":"Platelets"},{"key":"2025100314242654200_dkaf259-B31","doi-asserted-by":"publisher","first-page":"R135","DOI":"10.1530\/EC-18-0109","article-title":"Hypokalemia: a clinical update","volume":"7","author":"Kardalas","year":"2018","journal-title":"Endocr Connect"},{"key":"2025100314242654200_dkaf259-B32","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/cid\/ciz528","article-title":"The Pitt Bacteremia Score predicts mortality in nonbacteremic infections","volume":"70","author":"Henderson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025100314242654200_dkaf259-B33","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.4103\/jfmpc.jfmpc_150_20","article-title":"Utility of quick Sepsis-Related Organ Failure Assessment (qSOFA) score to predict outcomes in out-of-ICU patients with suspected infections","volume":"9","author":"Fernandes","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"2025100314242654200_dkaf259-B34","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap Consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2025100314242654200_dkaf259-B35","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1093\/jac\/dkad215","article-title":"Loading dose plus continuous\/extended infusion versus intermittent bolus of \u03b2-lactams for the treatment of Gram-negative bacteria bloodstream infections: a propensity score-adjusted retrospective cohort study","volume":"78","author":"Bavaro","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025100314242654200_dkaf259-B36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ijantimicag.2017.04.023","article-title":"Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a \u2018goldilocks\u2019 window","volume":"50","author":"Miglis","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2025100314242654200_dkaf259-B37","doi-asserted-by":"publisher","first-page":"ofad305","DOI":"10.1093\/ofid\/ofad305","article-title":"Optimizing the use of beta-lactam antibiotics in clinical practice: a test of time","volume":"10","author":"Tilanus","year":"2023","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/10\/2635\/63925494\/dkaf259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/10\/2635\/63925494\/dkaf259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:24:34Z","timestamp":1759515874000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/10\/2635\/8221513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,8,4]]},"published-print":{"date-parts":[[2025,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf259","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,4]]}}}